Analytical Data
-
Gene name
DEFA3/Defensin alpha 3
- Application
-
Alternative Names
Defensin, alpha 3 (HNP-3) (HP-3) (HP3) (HP 3-56) (Neutrophil defensin 2) (HNP-2) (HP-2) (HP2) (DEF3)
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P59666
-
Expression Region
39-94aa
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFA3, also known as Defensin alpha 3, is a member of the human defensin family, a group of small cationic peptides known for their antimicrobial properties. Initially discovered in neutrophils, defensins are integral components of the innate immune system, providing a first line of defense against pathogens such as bacteria, fungi, and viruses. DEFA3 exhibits not only antimicrobial activity but also plays crucial roles in modulating inflammation and wound healing. Given its multifunctional nature, research into DEFA3 has gained significant interest, particularly in understanding its mechanisms of action and potential therapeutic applications. Studies have shown that DEFA3 can interact with microbial membranes, leading to disruption and ultimately cell death, making it a candidate for developing new antimicrobial agents, especially in light of rising antibiotic resistance. Additionally, investigations into DEFA3’s role in immune responses have revealed its potential in treating inflammatory diseases and enhancing tissue repair processes. As such, DEFA3 serves as a model for exploring the broader implications of defensins in health and disease, paving the way for innovative approaches in drug design and therapeutic interventions. Researchers continue to explore recombinant expression systems to produce DEFA3 for in-depth studies, with the aim of harnessing its bioactivity for clinical applications.
